Details for New Drug Application (NDA): 211340
✉ Email this page to a colleague
NDA 211340 describes KATERZIA, which is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug. Additional details are available on the KATERZIA profile page.
The generic ingredient in KATERZIA is amlodipine benzoate. There are fifty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amlodipine benzoate profile page.
The generic ingredient in KATERZIA is amlodipine benzoate. There are fifty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amlodipine benzoate profile page.
Summary for 211340
| Tradename: | KATERZIA |
| Applicant: | Azurity |
| Ingredient: | amlodipine benzoate |
| Patents: | 13 |
Pharmacology for NDA: 211340
| Mechanism of Action | Calcium Channel Antagonists Cytochrome P450 3A Inhibitors |
Suppliers and Packaging for NDA: 211340
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| KATERZIA | amlodipine benzoate | SUSPENSION;ORAL | 211340 | NDA | Azurity Pharmaceuticals, Inc. | 52652-5001 | 52652-5001-1 | 1 BOTTLE in 1 CARTON (52652-5001-1) / 150 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | EQ 1MG BASE/ML | ||||
| Approval Date: | Jul 8, 2019 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Oct 16, 2037 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Apr 11, 2039 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Oct 6, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF TREATING HYPERTENSION | ||||||||
Complete Access Available with Subscription
